Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/CMAR.S71821 http://scihub22266oqcxt.onion/10.2147/CMAR.S71821 C4484697!4484697!26150735     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Manag+Res 2015 ; 7 (ä): 189-98 Nephropedia Template TP {{tp|p=26150735|t=2015. Treatment of metastatic colorectal cancer: focus on panitumumab |pdf=|usr=}}{{26150735}} gab.com Text Treatment of metastatic colorectal cancer: focus on panitumumab JO: Cancer Manag Res http://www.kidney.de/pget.php?&tw=1&pmid=26150735 #FOAvip Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC. Twit Text FOAVip Treatment of metastatic colorectal cancer: focus on panitumumab ????Cancer Manag Res http://www.kidney.de/pget.php?&tw=1&pmid=26150735 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26150735 #FOAvip English Wikipedia <ref>{{Cite pmid|26150735}}</ref> Treatment of metastatic colorectal cancer: focus on panitumumab #MMPMID26150735 Tay RY; Wong R; Hawkes EA Cancer Manag Res 2015[]; 7 (ä): 189-98 PMID26150735show ga Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC. äTreatment of metastatic colorectal cancer: focus on panitumumab (epmc).pdf DeepDyve Pubget Overpricing